Current Report Filing (8-k)
April 19 2022 - 4:32PM
Edgar (US Regulatory)
0000315545
false
0000315545
2022-04-19
2022-04-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 19, 2022
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Delaware |
|
001-36457 |
|
90-0031917 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932
(Address of Principal Executive Offices) (Zip Code)
(866) 594-5999
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2 below):
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☒ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
April 19, 2022, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has filed a
preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in connection with its 2022 Annual Meeting
of Stockholders (the “Annual Meeting”) to, among other things, seek stockholder approval of a reverse stock split proposal
and authorized share reduction proposal. The Annual Meeting is scheduled to be held on June 22, 2022.
Attached
hereto as Exhibit 99.1, and incorporated herein by reference, is a copy of the press release.
Other
Information
The
Company and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies in connection
with the proposals to be considered at the Annual Meeting. Stockholders may obtain additional information regarding the interests of
those participants by reading the Company’s preliminary proxy statement filed with the SEC on April 19, 2022, and, when they become
available, the Company’s definitive proxy statement and other definitive proxy materials, and the Company’s Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.
A
notice of internet availability of proxy materials with instructions for accessing the definitive proxy statement will be mailed to stockholders
as of the record date of April 25, 2022. Stockholders may obtain free copies of the preliminary proxy statement and the Company’s
other SEC filings electronically by accessing the SEC’s home page at http://www.sec.gov. Copies can also be obtained, free of charge,
upon written request to the Company, Attn: Secretary, 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932, (866) 594-5999.
Item
9.01. | Financial
Statements and Exhibits. |
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: April 19, 2022 |
|
|
|
|
PROVECTUS BIOPHARMACEUTICALS,
INC. |
|
|
|
By: |
/s/
Heather Raines |
|
|
Heather Raines |
|
|
Chief Financial Officer (Principal Financial Officer) |
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024